josh hardman
@Josh__Hardman
Followers
4K
Following
4K
Media
577
Statuses
3K
Covering all aspects of psychedelics at @Psyched_Alpha. Full of microplastics.
London, England
Joined December 2020
What do you think are the most important debates in the psychedelics ‘space’?
64
12
101
We asked psychedelic investors what they're most concerned about. The award for most entertaining response:
Q3’25 Investor Survey: What are Investors Most Concerned About? We take a close look at what psychedelics investors are most concerned about, using quantitative and qualitative data from our Q3'25 psychedelic investor survey. https://t.co/zGfYwWDU4Y
2
0
17
Official cause of death: "Ketamine Toxicity in the setting of hypertension." PDF of the suit:
0
0
3
Elsewhere, alleges Ward had missed multiple "mandatory" consultations, inc. one 11 days prior to his death. Mindbloom charged him a $150 no-show fee, suit claims, "yet failed to halt his access to the medication." Prior to Mindbloom, Ward was receiving twice-weekly Spravato.
1
0
3
Wrongful Death Suit Alleges Mindbloom’s At-Home Ketamine Program Led to 27-Year-Old’s Death Claims that Phillip Ward's medical history of depression, hypertension, tachycardia, and substance abuse should have excluded him from at-home ketamine program.
3
1
11
Trial finds no significant difference in effects between ketamine and midazolam administered twice-weekly for 4 weeks. Patients dosed twice-weekly, followed up for 6 months, widespread unblinding.
4
0
2
A European Model: Robert Schoevers on the Continent’s Growing Psychedelic Research Agenda @Josh__Hardman speaks to the principal investigator of of PsyPal, a large, EU-funded study of psilocybin in patients with palliative care needs. https://t.co/Dj6AlkI2PG
psychedelicalpha.com
Psychedelic Alpha’s Josh Hardman speaks with Robert Schoevers, Head of Psychiatry at University Medical Center Groningen and principal investigator of the EU-funded PsyPal study, about growing public...
1
1
6
In The Psychedelics Perceptions Tracker, we look at proxies of global interest in psychedelics. Explore: https://t.co/OU3f9OfK7X
0
2
9
A visit to a headache-inducing pharmacy, looking for headache-resolving medicine. Uji 🇯🇵
1
0
3
Ket: While each high lasts minutes. For some the damage to their bladder could last forever. https://t.co/FKwWsa2LBx
0
0
1
The UK government has launched a new campaign to alert young people to the dangers of ketamine, counterfeit medicines and adulterated THC vapes. https://t.co/ltRsgzGSD7
gov.uk
The government has launched a new campaign to alert young people to the dangers of ketamine, counterfeit medicines and adulterated THC vapes.
1
0
2
"year-long investigation reveals how a small group of Silicon Valley elites sought to capture the psychedelic therapy industry — using a network of affiliated organizations to scapegoat critics while pressuring regulators to approve their botched MDMA..." https://t.co/g9u9IwHCso
psymposia.com
A year-long investigation reveals how a small group of Silicon Valley elites sought to capture the psychedelic therapy industry — using a network of affiliated organizations to scapegoat critics...
1
4
9
Psymposia shares its latest: a 201-page, 13-chapter tome that it calls 'The Psychedelic Syndicate'. It also calls it "Psymposia's magnum opus."
7
2
17
An absolute corker from Citeline yesterday! According to them/Evaluate, Novo Nordisk is working with MindMed to develop LSD, and atai is working with Compass to develop psilocybin.
When you know a little about a subject, you realise how often major outlets get it a little wrong. Compass Therapeutics(!) yet to share Ph 3 psilocybin readout, according to the second & third sentences of a PharmaVoice article out today. (The link is to a private Google Doc.)
0
0
2